Overview
IMRX market data
Price History
IMRX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.03 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.33 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -9,610.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.90 – $10.08 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $293.1M · P/B 1.94 · P/S 586.16.
Company News
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For ThursdayBenzinga · Aug 6, 2026, 2:12 PM
HC Wainwright & Co. Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $14Benzinga · Aug 6, 2026, 11:05 AM
8-K filing — Immuneering Corp (IMRX)SEC EDGAR · Aug 5, 2026, 11:41 AM
Immuneering Q2 EPS $(0.27), InlineBenzinga · Aug 5, 2026, 11:38 AM
Immuneering Publishes New Findings In Cancer Research Characterizing The Differentiated Mechanism And Broad Preclinical Activity Of Atebimetinib; Atebimetinib Showed Broad Antitumor Activity Across KRAS-, NRAS-, And BRAF-mutant Models, Including Colorectal, Lung, And Melanoma, By Resisting The RAF-Mediated Bypass Signaling That Has Constrained Other MEK InhibitorsBenzinga · Jul 21, 2026, 8:13 PM
Needham Maintains Buy on Immuneering, Raises Price Target to $18Benzinga · Jul 20, 2026, 10:33 AM
Cantor Fitzgerald Initiates Coverage On Immuneering with Overweight RatingBenzinga · Jul 8, 2026, 1:15 PM
Immuneering Appoints Andrew Gengos CFO, Effective July 16Benzinga · Jun 15, 2026, 11:40 AM
Immuneering Doses First Patient In MAPKeeper 301 Pivotal Phase 3 Clinical Study Of Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel To Treat Metastatic Pancreatic Cancer PatientsBenzinga · Jun 11, 2026, 11:33 AM
Immuneering shares are trading lower. The company announced updated clinical data from its ongoing Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma.Benzinga · Jun 1, 2026, 3:16 PM